Bifidobacterium bifidum

ApprovedBiologic

SSun Yat-sen University

Bifidobacterium bifidum is one of 85 biologic programs targeting Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

Liver CancerActive, not recruiting

LeukemiaPhase 2

Active, not recruiting

Liver CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

508 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

51 2

Trexall

Alnylam Pharmaceuticals

Phase 3

31 3

Fludara

Sanofi

Phase 3

22 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

58 5

Rituxan

Roche

Phase 3

16 6

Idamycin

Pfizer

Phase 3

10 7

Neoral

Novartis

Phase 3

9 8

Oncovin

Eli Lilly

Phase 3

9 9

Novantrone

Pfizer

Phase 3

8 10

Leukine

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leukemia1 trial

Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia

Enrolling by invitation·NNational Institute of Pediatrics, Mexico·Phase 2·NCT06560879·120 enrolled

Complication1 trial

Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Complications in PD

Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 1/2·NCT06719596·68 enrolled

Liver Cancer1 trial

Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy

Unknown status·SSun Yat-sen University·Phase 1/2·NCT05620004·30 enrolled

Injury1 trial

Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics

Unknown status·PPeking University Third Hospital·Phase 4·NCT05730777·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Bifidobacterium bifidum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Bifidobacterium bifidum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Bifidobacterium bifidum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sun Yat-sen University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: SSun Yat-sen University

Bifidobacterium bifidum

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leukemia1 trial

Complication1 trial

Liver Cancer1 trial

Injury1 trial

References

Drug Info

Quick Facts

Related News